Journal ArticleDOI
The metabolic syndrome X and peripheral cortisol synthesis.
TLDR
Evidence is presented, that by the action of 11 beta-hydroxysteroid dehydrogenase 1 (11 beta HSD1) higher intracellular cortisol concentration may be created that may be relevant to induce insulin resistance and metabolic disturbances.Abstract:
The metabolic syndrome X and Cushing's syndrome show similar symptoms but one major difference: Plasma cortisol is not elevated in the metabolic syndrome. Evidence is presented, that by the action of 11 beta-hydroxysteroid dehydrogenase 1 (11 beta HSD1) higher intracellular cortisol concentration may be created that may be relevant to induce insulin resistance and metabolic disturbances. Regulation of 11 beta HSD1 expression by hormones, growth factors, cytokines and transcription factors enables tissue specific adjustments of glucocorticoid receptor activation by cortisol. Specific inhibition of 11 beta HSD1 would help to understand aspects of the pathogenesis of syndrome X and to develop new therapeutic perspectives.read more
Citations
More filters
Journal ArticleDOI
(Patho)physiological Significance of the Serum- and Glucocorticoid-Inducible Kinase Isoforms
Florian Lang,Christoph Böhmer,Monica Palmada,Guiscard Seebohm,Nathalie Strutz-Seebohm,Volker Vallon +5 more
TL;DR: The serum- and glucocorticoid-inducible kinase-1 (SGK1) is ubiquitously expressed and under genomic control by cell stress and hormones, and may play an active role in a multitude of pathophysiological conditions.
Journal ArticleDOI
Regulation of Glucose Transporter SGLT1 by Ubiquitin Ligase Nedd4‐2 and Kinases SGK1, SGK3, and PKB
Michael Dieter,Monica Palmada,Jeyaganesh Rajamanickam,Atakan Aydin,Andreas Busjahn,Christoph Boehmer,Friedrich C. Luft,Florian Lang +7 more
TL;DR: Overactivity of SGK1 may lead not only to excessive ENaC activity and hypertension but also to enhanced SGLT1 activity and obesity.
Journal ArticleDOI
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.
Susan Kralisch,Johannes E. M. N. Klein,Ulrike Lossner,Matthias Blüher,Ralf Paschke,Michael Stumvoll,Mathias Fasshauer +6 more
TL;DR: Results show a differential regulation of visfatin mRNA by insulin resistance-inducing hormones, supporting the view that this adipo-cytokine might be an interesting novel candidate linking core components of the metabolic syndrome such as obesity and insulin resistance.
Journal ArticleDOI
The Metabolic Syndrome and Cardiovascular Risk in Cushing's Syndrome
TL;DR: Study results suggest that an increased cardiovascular risk also may persist in patients who undergo treatment with exogenous glucocorticoids after therapy withdrawal, and this could be of great clinical relevance and should be investigated thoroughly.
Patent
Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders
TL;DR: Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders as mentioned in this paper.